Match!
Mark Peakman
King's College London
333Publications
52H-index
8,909Citations
Publications 333
Newest
Published on May 1, 2019in International Journal of Pharmaceutics4.21
M. Dul (Cardiff University), Tatjana Nikolic11
Estimated H-index: 11
(LUMC: Leiden University Medical Center)
+ 12 AuthorsMark Peakman52
Estimated H-index: 52
Antigen specific immunotherapy aims to tolerise patients to specific autoantigens that are responsible for the pathology of an autoimmune disease. Immune tolerance is generated in conditions where the immune response is suppressed and thus gold nanoparticles (AuNPs) are an attractive drug delivery platform due to their anti-inflammatory effects and their potential to facilitate temporal and spatial delivery of a peptide autoantigen in conjunction with pro-tolerogenic elements. In this study we h...
Published on Jan 9, 2019
Iria Gomez-Tourino6
Estimated H-index: 6
,
Yogesh Kamra1
Estimated H-index: 1
+ 2 AuthorsMark Peakman52
Estimated H-index: 52
Published on Jan 1, 2019in The Lancet Diabetes & Endocrinology24.54
Mark A. Atkinson82
Estimated H-index: 82
(UF: University of Florida),
Bart O. Roep58
Estimated H-index: 58
(City of Hope National Medical Center)
+ 2 AuthorsMark Peakman52
Estimated H-index: 52
(HealthPartners)
Summary With the conceptual advance about four decades ago that type 1 diabetes represents an autoimmune disease, hope arose that immune-based therapies would soon emerge to prevent and reverse the disorder. However, despite dozens of clinical trials seeking to achieve these goals, the promise remains unfulfilled, at least in a pragmatic form. With the benefit of hindsight, several important reasons are likely to account for this disappointing outcome, including failure to appreciate disease het...
Published on Jan 1, 2019in The Lancet Diabetes & Endocrinology24.54
Bart O. Roep58
Estimated H-index: 58
(City of Hope National Medical Center),
Daniel C S Wheeler1
Estimated H-index: 1
('KCL': King's College London),
Mark Peakman52
Estimated H-index: 52
(HealthPartners)
Summary Precision medicine has emerged as a mantra for therapeutic approaches to complex diseases. The defining concept relies on a detailed insight into disease pathogenesis and therapeutic mechanism. Although the type 1 diabetes field has gained new insights into disease endotypes and indications of efficacy for several therapies, none of these is yet licensed, partly because of immune suppressive side-effects beyond control of islet autoimmunity. New strategies designed to regulate the immune...
Published on Jan 1, 2019in Schizophrenia Bulletin7.29
Thomas Pollak11
Estimated H-index: 11
('KCL': King's College London),
Jonathan P Rogers1
Estimated H-index: 1
('KCL': King's College London)
+ 4 AuthorsPhilip McGuire105
Estimated H-index: 105
('KCL': King's College London)
Published on Dec 1, 2018in Scientific Reports4.01
Johan Verhagen1
Estimated H-index: 1
(Guy's Hospital),
Emma L. Smith1
Estimated H-index: 1
(UCB)
+ 2 AuthorsMark Peakman52
Estimated H-index: 52
(HealthPartners)
Antigen-specific immunotherapy of autoimmune disease currently remains the only potentially curative approach. However, translation of promising pre-clinical results into successful clinical application has proven challenging. In part, this is because pre-clinical findings in mouse models have to be redesigned for human application due to differences in MHC II. To reduce the gap between pre-clinical and clinical studies, we have created a novel mouse model that expresses human HLA-DR4, but no en...
Published on Aug 1, 2018in Journal of Clinical Investigation12.28
Lorraine Yeo3
Estimated H-index: 3
,
Alyssa Woodwyk1
Estimated H-index: 1
(WMU: Western Michigan University)
+ 13 AuthorsGarry Dolton16
Estimated H-index: 16
(Cardiff University)
In type 1 diabetes, cytotoxic CD8+ T cells with specificity for β cell autoantigens are found in the pancreatic islets, where they are implicated in the destruction of insulin-secreting β cells. In contrast, the disease relevance of β cell–reactive CD8+ T cells that are detectable in the circulation, and their relationship to β cell function, are not known. Here, we tracked multiple, circulating β cell–reactive CD8+ T cell subsets and measured β cell function longitudinally for 2 years, starting...
Published on Jun 29, 2018in Frontiers in Immunology4.72
Garry Dolton16
Estimated H-index: 16
(Cardiff University),
Efthalia Zervoudi2
Estimated H-index: 2
(Cardiff University)
+ 11 AuthorsMeriem Attaf7
Estimated H-index: 7
(Cardiff University)
Peptide-MHC (pMHC) multimers have become the 'gold standard' for the detection and isolation of antigen-specific T-cells but recent evidence shows that normal use of these reagents can miss fully functional T-cells that bear T-cell receptors (TCRs) with low affinity for cognate antigen. This issue is particularly pronounced for anti-cancer and autoimmune T-cells as self-reactive T-cell populations are enriched for low affinity TCRs due to the removal of cells with higher affinity receptors by im...
Published on May 1, 2018in Diabetes7.20
Yuk-Fun Liu5
Estimated H-index: 5
,
Jake Powrie18
Estimated H-index: 18
+ 6 AuthorsMark Peakman52
Estimated H-index: 52
Background: Peptide immunotherapy (PIT) aims to modulate immune responses to specific antigens in order to restore immune tolerance. Recently, we reported outcomes of a phase 1b study of PIT at type 1 diabetes onset, showing safety, tolerability and changes in immune regulation pathways, following up to 12 doses of 10μg of a single proinsulin peptide that is naturally processed and presented by HLA-DR4 ( DRB1*0401 ). Preclinical PIT studies show that multiple peptides in combination enhance tole...
12345678910